1. Exploring the morphological and functional retinal changes after dexamethasone intravitreal implant (Ozurdex®) in macular edema due to retinal vein occlusion
- Author
-
Adele Chiaravalloti, Fabio Scarinci, Francesco Oddone, Monica Varano, Mariacristina Parravano, Barbara Boccassini, Massimiliano Tedeschi, and Paola Giorno
- Subjects
Adult ,Male ,medicine.medical_specialty ,Visual acuity ,Retinal Vein ,Anti-Inflammatory Agents ,Visual Acuity ,Dexamethasone ,Macular Edema ,Cellular and Molecular Neuroscience ,chemistry.chemical_compound ,Retinal Vein Occlusion ,polycyclic compounds ,medicine ,Dexamethasone Intravitreal Implant ,Humans ,Prospective Studies ,skin and connective tissue diseases ,Macular edema ,Aged ,Aged, 80 and over ,Drug Implants ,business.industry ,Retinal ,General Medicine ,Middle Aged ,medicine.disease ,Sensory Systems ,Surgery ,Ophthalmology ,chemistry ,Intravitreal Injections ,Regression Analysis ,Female ,sense organs ,Implant ,medicine.symptom ,Visual Fields ,business ,Microperimetry ,hormones, hormone substitutes, and hormone antagonists ,Tomography, Optical Coherence ,medicine.drug - Abstract
Purpose: To explore functional and morphological retinal changes 6 months after dexamethasone intravitreal implant (DEX implant) for the treatment of macular edema due to central or branch retinal vein occlusion (CRVO, BRVO). Procedures: In this prospective interventional case series patients underwent a complete ophthalmological examination at baseline and monthly, including best-corrected visual acuity (BCVA), spectral domain-optical coherence tomography and microperimetry. Fluorescein angiography was performed at baseline and at 4 months. All patients were treated with a DEX implant and retreated according to predefined criteria starting from month 4. Results: Sixteen patients (mean age 66 ± 13 years, 14 CRVO, 2 BRVO) were included. At 6 months mean retinal sensitivity improved from 9.7 ± 4.6 to 13.6 ± 5.4 dB (p < 0.0001) while mean BCVA improved from 52.4 ± 16.2 to 66.1 ± 16.6 (p < 0.0001). Mean central retinal thickness decreased from 708.3 ± 151.01 to 362.7 ± 177.4 μm (p < 0.0001); 56.2% of eyes were retreated at month 4. Conclusions: At 6 months DEX implant led to a significant improvement in retinal sensitivity and visual acuity associated with a reduction of retinal thickness in patients with macular edema due to retinal vein occlusion.
- Published
- 2013